Canadian International Pharma Corp. Announces Proposed Share Consolidation and Non-brokered Private Placement
CW15458074.1
CANADIAN INTERNATIONAL PHARMA CORP.
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR
DISSEMINATION IN THE UNITED STATES
News Release No: 20-04
Trading symbol: TSX-V – NEX: CIP.H
Canadian International Pharma Corp. Announces Proposed Share Consolidation and Non-brokered
Private Placement
West Vancouver, British Columbia – August 21, 2020 – Canadian International Pharma Corp. (the
“Company” or “CIPC”) announces that it intends to proceed with a consolidation of its common shares
(each, a “ Share”) on the basis of ten (10) pre-consolidation Shares for one (1) post-consolidation Share
(the “Consolidation”).
Currently, a total of 38,453,013 Shares are issued and outstanding. Accordingly, if the Consolidation is
put into effect, a total of 3,845,301 Shares would be issued and outstanding, assuming there are no other
changes in the issued capital of the Company. Ther e is currently no maximu m number of authorized
Shares. The Consolidation will provide CIPC with in creased flexibility to seek additional financing
opportunities and is subject to approval of the TS X V e n t u r e E x c h a n g e . T h e r e i s n o n a m e c h a n g e i n
conjunction with the Consolidation.
The Company also announces that, subject to regulatory approval, it has arranged a non-brokered private
placement financing (the “ Financing”) of up to 8,888,888 units (each, a “ Unit”) at a price of $0.1125 per
Unit for gross proceeds of up to $1,000,000. Each Un it consists of one post-Consolidation Share and one
share purchase warrant (each, a “ Warrant”). One Warrant entitles the holder thereof to purchase one
additional post-Consolidation Share of the Company at a price of $0.15 per post-Consolidation Share for a
period of one year from closing of the Financing.
The proceeds from the Financing will be used for general working capital.
All securities issued in connection with the Financing will be subject to a statut ory hold period expiring
four months and one day after closing of the Financ ing. Completion of the Financing is subject to a
number of conditions, including, without limitation, receipt of all regulatory approvals, including
approval of the TSX Venture Exchange.
None of the securities sold in connection with th e Financing are registered under the United States
Securities Act of 1933, as amended, and no such secu rities may be offered or sold in the United States
absent registration or an applicable exemption from the registration requirements. This news release shall
not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the
securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
For further information, contact Douglas L. Mason at 604.922.2030
CANADIAN INTERNATIONAL PHARMA CORP.
“Douglas L. Mason”
Douglas L. Mason, CEO
Neither the TSX Venture Exchange nor it s Regulation Services Provider (as that term is defined in policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.